Clinical Trial Update: Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial of bortezomib plus vorinostat in recurrent mantle cell lymphoma or recurrent/diffuse large B-cell lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• Vorinostat (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-08-07